{"id":985423,"date":"2026-07-28T07:04:35","date_gmt":"2026-07-28T11:04:35","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-announces-positive-topline-results-from-reclaim-phase-2-trial-of-pemvidutide-in-alcohol-use-disorder\/"},"modified":"2026-07-28T07:04:35","modified_gmt":"2026-07-28T11:04:35","slug":"altimmune-announces-positive-topline-results-from-reclaim-phase-2-trial-of-pemvidutide-in-alcohol-use-disorder","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-announces-positive-topline-results-from-reclaim-phase-2-trial-of-pemvidutide-in-alcohol-use-disorder\/","title":{"rendered":"Altimmune Announces Positive Topline Results from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <em>Pemvidutide 2.4 mg delivered a statistically significant and clinically meaningful reduction in heavy drinking days, the primary endpoint of the trial\u00a0<\/em>\n      <\/p>\n<p align=\"center\">\n        <em>Important secondary endpoints were also met, including two-level reduction in WHO risk drinking levels and zero heavy drinking days, both of which are recognized by the FDA as registrational endpoints<\/em>\n      <\/p>\n<p align=\"center\">\n        <em>A generally favorable tolerability profile was observed in the trial<\/em>\n      <\/p>\n<p align=\"center\">\n        <em>Conference call to be held today at 8:00 am ET<\/em>\n      <\/p>\n<p>GAITHERSBURG, Md., July  28, 2026  (GLOBE NEWSWIRE) &#8212; Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company focused on serious liver diseases, today announced positive topline results from the RECLAIM Phase 2 trial evaluating pemvidutide, an investigational balanced glucagon\/GLP-1 dual receptor agonist, in patients with moderate to severe alcohol use disorder (AUD). The trial met its primary endpoint with a highly statistically significant reduction in heavy drinking days (HDD) versus placebo, with consistent positive results across important secondary endpoints, including the World Health Organization (WHO) Risk Drinking Levels (RDL), zero HDD and phosphatidyl ethanol (PEth) levels.\u00a0 A generally favorable tolerability profile was observed in the trial. The Company plans to request an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) based on the results of the trial.<\/p>\n<p>\u201cWe are extremely encouraged by these compelling topline results, which showed a highly significant reduction in heavy drinking days and nearly two-thirds of patients treated with pemvidutide achieving a two-level reduction in their WHO-RDL, a clinically meaningful outcome for these patients,\u201d said Christophe Arbet-Engels, M.D., Ph.D., Chief Medical Officer at Altimmune. \u201cThese data reflect pemvidutide\u2019s strong and consistent efficacy across important measures of drinking behavior, together with a generally favorable tolerability profile in this difficult-to-treat disorder. Given the known detrimental effects of alcohol on the liver, the liver-directed impact of glucagon in pemvidutide may provide further benefit in the treatment of AUD over GLP-1 alone, underscoring pemvidutide\u2019s promising potential differentiation.\u201d<\/p>\n<p>\n        <strong>Efficacy Data <\/strong>\n      <\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"max-width:22%;width:22%;min-width:22%;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;text-align: center;vertical-align: middle\">\n            <strong>Endpoint<\/strong>\n          <\/td>\n<td style=\"max-width:21%;width:21%;min-width:21%;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle\">\n            <strong>Placebo<\/strong>\n          <\/td>\n<td style=\"max-width:21%;width:21%;min-width:21%;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle\">\n            <strong>Pemvidutide<\/strong>\n          <\/td>\n<td style=\"max-width:21%;width:21%;min-width:21%;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle\">\n            <strong>Treatment Effect<\/strong>\n          <\/td>\n<td style=\"max-width:15%;width:15%;min-width:15%;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle\">\n            <strong>P-value<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;text-align: center;vertical-align: middle\">Change from baseline in HDD\/Week at Week 24 (Primary Endpoint)<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle\">-2.75 (LS mean)<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle\">-4.20 (LS mean)<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle\">-1.45 (LS mean difference)<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle\">0.0014<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;text-align: center;vertical-align: middle\">2-level Reduction in WHO-RDL<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle\">34.8% (16\/46)<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle\">64.4% (29\/45)<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle\">Odds Ratio 3.31<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle\">0.0049<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;text-align: center;vertical-align: middle\">Zero HDD in Week 21 through Week 24<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle\">17.4% (8\/46)<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle\">42.2% (19\/45)<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle\">Odds Ratio 3.84<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle\">0.0066<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;text-align: center;vertical-align: middle\">Change from baseline in Percent of Days with Abstinence<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle\">20.5% (LS mean)<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle\">38.9% (LS mean)<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle\">18.4% (LS mean difference)<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle\">0.0075<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;text-align: center;vertical-align: middle\">Change from baseline in Serum PEth at Week 24<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle\">22.0 (LS mean)<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle\">-153.4 (LS mean)<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle\">\u00a0-175.3 (LS mean difference)<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle\">&lt;0.0001<\/td>\n<\/tr>\n<tr>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<\/tr>\n<\/table>\n<p>\n        <strong>Key efficacy results included<\/strong>:<\/p>\n<ul type=\"disc\">\n<li>Statistically significant reduction in the primary endpoint of HDD per week versus placebo (p=0.0014)<\/li>\n<li>Statistically significant results on secondary endpoints, including two that are registrational endpoints\n<ul type=\"disc\">\n<li>Two-level reduction in WHO Risk Drinking Levels versus placebo (p=0.0049)<\/li>\n<li>Zero heavy drinking days versus placebo (p=0.0066)<\/li>\n<\/ul>\n<\/li>\n<li>Statistically significant change in percent of days with abstinence versus placebo (p=0.0075)<\/li>\n<li>Statistically significant reduction in PEth levels versus placebo (p&lt;0.0001)<\/li>\n<li>Statistically significant reduction in body weight, as measured by a placebo-adjusted difference in change from baseline of 9.1% at 24 weeks (p&lt;0.0001), with no evidence of plateauing<\/li>\n<\/ul>\n<p>\n        <strong>Safety and Tolerability Data<\/strong>\n      <\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"max-width:34%;width:34%;min-width:34%;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">\n            <strong>Adverse Event (AE)<\/strong>\n          <\/td>\n<td style=\"max-width:33%;width:33%;min-width:33%;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: top\">\n            <strong>Placebo<\/strong><br \/>\n            <br \/>\n            <strong>(N=50)<\/strong>\n          <\/td>\n<td style=\"max-width:33%;width:33%;min-width:33%;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: top\">\n            <strong>Pemvidutide 2.4mg<\/strong><br \/>\n            <br \/>\n            <strong>(N=50)<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">Serious AEs<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: top\">1 (2%)<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: top\">2 (4%)<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">Severe AEs<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: top\">3 (6%)<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: top\">6 (12%)<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">Nausea<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: top\">12 (24%)<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: top\">22 (44%)<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">Vomiting<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: top\">3 (6%)<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: top\">9 (18%)<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">Diarrhea<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: top\">5 (10%)<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: top\">10 (20%)<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">Constipation<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: top\">3 (6%)<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: top\">13 (26%)<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">Treatment discontinuations<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: top\">11 (22%)<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: top\">10 (20%)<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">Study drug-related AEs leading to treatment discontinuation<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: top\">0 (0%)<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: top\">5 (10%)*<\/td>\n<\/tr>\n<tr>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<\/tr>\n<\/table>\n<p>*2 vomiting, 1 constipation, 1 fatigue, 1 exacerbation of hemorrhoids<\/p>\n<p>Pemvidutide was generally well tolerated in this patient population with high unmet need. <br \/>The new, simple two-step titration for the 2.4 mg dose may improve gastrointestinal (GI) tolerability compared to prior pemvidutide titration schemes. The majority of adverse events were mild to moderate in severity. There was one serious adverse event (SAE) (hyponatremia) in the pemvidutide arm that was deemed possibly related to treatment drug by the principal investigator.<\/p>\n<p>\u201cAs someone who has dedicated his career to understanding and treating alcohol use disorder, I recognize the significance of these findings, particularly given the current attention on the adverse health impact of heavy drinking. These results provide a consistent picture of treatment benefit on self-reported drinking outcomes, supported by objective PEth biomarker evidence,\u201d said Henry Kranzler, M.D., Karl E. Rickels Professor of Psychiatry and Director, Center for Studies of Addiction, University of Pennsylvania Perelman School of Medicine, and Principal Investigator of the RECLAIM trial. \u201cThese data underscore the potential for pemvidutide to address multiple dimensions of alcohol use disorder by supporting abstinence and reducing heavy drinking, findings that build on prior evidence of its activity in the liver.\u201d<\/p>\n<p>\u201cThese top-line data strengthen our confidence in pemvidutide&#8217;s differentiation and its potential to benefit people living with MASH, AUD and ALD, who currently have limited treatment options,\u201d said Jerry Durso, Chief Executive Officer and Chairman of the Board of Altimmune. \u201cThese results represent yet another important milestone for Altimmune as we continue to execute on our goal to bring pemvidutide to patients with serious liver diseases while creating value for shareholders.\u201d <\/p>\n<p>Based on these data, Altimmune plans to request an End-of-Phase 2 (EOP2) meeting with the FDA to discuss the path forward for pemvidutide in AUD. Results from the RECLAIM trial will be submitted for presentation at a forthcoming medical conference and for publication in a peer-reviewed journal.<\/p>\n<p>\n        <strong>Conference Call Information<\/strong><br \/>\n        <br \/>Altimmune will host a conference call and webcast at 8:00 a.m ET today to discuss the RECLAIM topline data. The conference call will be webcast live on Altimmune\u2019s Investor Relations (IR) \u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=wiqMD3FzMKguoUFAiYPylrURQkTPREBGOGQzKk8VKHMqMS4OHhGEqDqn2DwxS09pGmPfowtX3L0UhJEJVqvPfy-j8QmnLgHdypJGEQ-OvIMlc9Q9Rr_Ji66nGAZptsLU\" rel=\"nofollow\" target=\"_blank\">website.<\/a> Participants who would like to join by phone may register <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-fPXa-TUDRA20wOtu87lVnEbozGVkVBSU6TXYHppqFSzoSThXB5mXLiabIQikr4AWYV15cD3zx9LrDxzhP6PxrAuMscBfEuOXX0LYhYBVU_JS_4WodDuNtgwx4nkFASCmsjGJP13NZdkA1cn9INZ0hRyIoTCcLQ3L2TrJ0qN8m8=\" rel=\"nofollow\" target=\"_blank\">here<\/a> to receive the dial-in numbers and unique pin to access the call. Following the conclusion of the call, the webcast will be available for replay on the IR page of the company\u2019s website.<\/p>\n<p>\n        <strong>About RECLAIM<\/strong>\n      <\/p>\n<p>RECLAIM (<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=lJJf9fXb4VhcXjhQlRDeLxe_UDQFig-RASv_tBnG6U3_1Arri0LkvtElaNjqzYXT08JzbAkwy-BK9Bzj9240GSmJvj12Kn2QAGFk_MEznrjYjDb6SBkGH_wZE5rVufvRGGLuVvrZ43J5AcGFXesGxq7Dn1YsYgCG0YhuI81Y_i4SZLtX2CexBxMZe5b8Wh8hmim4sqtLg8cRTfLCbXzS-k29f5iVq6tU9wk_oC--f5COW6UB_qUyQSA_AQxmTdMF3jmtOFrXh04CoFprXFRwSjsSdekeYmjmgsmRNuA08a6kUgRFaWCXNjoROO8NBUDX2_8XeT08D88MM7Tf6IdOeb40uMqgRHMt8FmFtqmNQXAmiY0Y80vOa0mu4d2Ie_i6u-s0uyPJ3MF0lmiY78NLGmqmeyNjxodBxfhAcRFwkyE3OgbunzyqGJoZj3dSkXacdUo0P1STvRcsDDAZje8mM6j-mqn7fkSQmXuQu-FW8OvnlZpWuS5lEKrTr_7QPV8fpOcjkr3Hn-OdWknFrVG5pqPM6zzkaOI2llDWQ2jTrNw=\" rel=\"nofollow\" target=\"_blank\">NCT06987513<\/a>) is a Phase 2 trial evaluating the safety and efficacy of pemvidutide in Alcohol Use Disorder (AUD) patients with BMI &gt;25 kg\/m<sup>2<\/sup>, and is the first Phase 2 multicenter study evaluating a dual glucagon-GLP-1 agonist in AUD to report results. Approximately 100 patients were randomized 1:1 to receive either 2.4 mg pemvidutide or placebo once weekly for 24 weeks. The primary endpoint of the trial was the change from baseline in the average number of heavy drinking days (HDD) per week, with secondary endpoints including the proportion of patients achieving a 2-level reduction in\u00a0World Health Organization\u00a0(WHO) Risk Drinking Levels (RDL), zero HDD, and absolute change from baseline in average levels of phosphatidylethanol (PEth), an objective serum biomarker of alcohol intake. The 2-level reduction in WHO risk drinking levels and zero HDD are recognized by the FDA as registrational endpoints.<\/p>\n<p>\n        <strong>About AUD<\/strong>\n      <\/p>\n<p>Alcohol use disorder (AUD) is a medical condition driven by an impaired ability to stop or control the harmful consumption of alcohol. AUD can also lead to serious health consequences, including liver cirrhosis, cardiovascular disease, and cancer. Additionally, many patients with AUD present with comorbidities including excess fat in the liver and obesity, further amplifying their risk for poor outcomes. The\u00a0World Health Organization\u00a0estimates that harmful alcohol consumption is the seventh leading cause of global death and disability, with alcohol accounting for 50% of all liver-related deaths.<\/p>\n<p>Today, it is estimated that 28 million adults in the\u00a0U.S.\u00a0suffer from AUD. Patients with AUD are characterized as mild, moderate or severe according to the DSM-5 criteria with approximately 12 million having moderate or severe forms of the disease. Only three drugs for AUD have been approved by the FDA, but these agents have limited efficacy for AUD and its comorbidities and are used by less than 2% of patients. There is a substantial unmet need for new and more effective treatments that not only reduce alcohol cravings and heavy drinking days but also can address the numerous other risks of the disease.<\/p>\n<p>\n        <strong>About <\/strong><br \/>\n        <strong>Pemvidutide<\/strong>\n      <\/p>\n<p>Pemvidutide is a novel, investigational peptide with balanced 1:1 glucagon\/GLP-1 dual receptor agonist activity, in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). The activation of glucagon receptors results in direct effects on the liver, including reductions in liver fat, inflammation and fibrosis, while GLP-1 receptors mediate metabolic effects such as appetite suppression and weight loss, and may play a role in pathways related to craving and reward.<\/p>\n<p>The FDA granted Fast Track designations to pemvidutide for the treatment of MASH and AUD, as well as Breakthrough Therapy Designation for MASH. In December 2025, the Company announced 48-week data from the IMPACT Phase 2b trial in MASH. In July 2026, the Company announced results from the RECLAIM Phase 2 trial in AUD. The RESTORE trial in ALD was initiated in July 2025, and enrollment completion is expected in the third quarter 2026. The Company plans to initiate the PERFORMA Phase 3 trial, a multinational, randomized, double-blind, placebo-controlled, parallel-group study of pemvidutide in patients with MASH in the third quarter of 2026.<\/p>\n<p>\n        <strong>About Altimmune<\/strong>\n      <\/p>\n<p>Altimmune is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company\u2019s lead candidate, pemvidutide, is a unique dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of MASH, AUD and ALD. For more information, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=CkSjKQddwsFo7H6h1rB0xZCeopsUZ-MqgVPwNYc1tyF_orV5deOHS0hBL4VSdDots6E8Kos4JfM1JMf4-dWhj82vmbSBHhNMn08b6ulU6eTpZoKnw9EBW-nVsQ-Q5l7bhHP7HqYlpdBRr57OnvziaXN8gcEmB_KtF-sOmyyHIDNUQQRVEZAHFmoJ6zMGVCLaQDeGyFT4njSvIe73KhhXlxhv9xv0eA9wjkejAWmLHgvVF8KTf21uAnh9zw6c18qctwKJncMK_uVnhGk08zf2HvCmZtlOGBec-F0iSqKaDfRIcFUAhmtrtOzlgH6NUugd5DEatwQO5LpsQz2sT9nyKAs6VuPg8gUdIZZbURLkvMTxKAPj_mnbnLuhWOomN6mfJfe1fZ_JWbzGWAkT8tup0oVVFVUnO5tyKn9j836pduvFTbnLrqvcVWs1id6styRu_ES3wf0I9AxAnbGyTyIzqY8AKxw8FwCy_VnXEWVpe0w=\" rel=\"nofollow\" target=\"_blank\">www.altimmune.com<\/a>.<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p>This press release has been prepared by Altimmune, Inc. (&#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;Altimmune&#8221; or the &#8220;Company&#8221;) and includes certain \u201cforward-looking statements\u201d within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to future financial or business performance, conditions, plans, prospects, trends, or strategies and other financial and business matters, including without limitation, the timing of key milestones for our clinical assets, the performance of our drug candidates in ongoing and future clinical trials including the RECLAIM trial (topline results of which are described herein), the ongoing RESTORE trial and the planned PERFORMA trial, evaluating pemvidutide in patients with MASH, AUD and ALD, the potential benefits of Fast Track and Breakthrough Therapy Designations and the prospects for regulatory approval, commercializing, market size, market potential, competitive landscape, or selling any product or drug candidates. In addition, when or if used in this presentation, the words \u201cmay,\u201d \u201ccould,\u201d \u201cshould,\u201d \u201canticipate,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201cpredict,\u201d \u201cpotential\u201d, \u201csuggest\u201d and similar expressions and their variants, as they relate to the Company may identify forward-looking statements. The Company cautions that these forward-looking statements are subject to numerous assumptions, risks, and uncertainties, which change over time. Important factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including risks such as delays in regulatory review, manufacturing and supply chain interruptions, access to clinical sites, enrollment, adverse effects on healthcare systems and disruption of the global economy; patient baseline characteristics which may vary and impact the success of future trials; the reliability of the results of studies relating to human safety and possible adverse effects resulting from the administration of the Company\u2019s product candidates; the Company\u2019s ability to manufacture clinical trial materials on the timelines anticipated; whether the FDA will agree with the Company&#8217;s proposed development and regulatory strategy for pemvidutide in AUD, including following any End-of-Phase 2 meeting; the risk that results from the RECLAIM trial may not be predictive of results in the RESTORE trial, the planned PERFORMA trial, or any other future or larger clinical trial; the Company&#8217;s need for substantial additional capital to complete development of pemvidutide, which may not be available on acceptable terms or at all; competition from other companies developing treatments for MASH, AUD and ALD; and the success of future product advancements, including the success of current and future clinical trials. Further information on the factors and risks that could affect the Company&#8217;s business, financial conditions and results of operations are contained in the Company\u2019s filings with the U.S. Securities and Exchange Commission, including under the heading \u201cRisk Factors\u201d in the Company\u2019s latest annual report on Form 10-K, quarterly report on Form 10-Q and our other filings with the SEC, which are available at www.sec.gov.<\/p>\n<p>\n        <strong>Investor Contact:<br \/><\/strong>Luis Sanay, CFA<br \/>Vice President, Investor Relations<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Ps6bGmya2QJRJ3PP_-aNeP9tOqz4axiBN5HVlASKJoLjftFA-VSAwotYvvn3V7FbuVSRyTIrMPLd91s3b8O4Y8FytEpi1ifrRyKHghAOJ3c=\" rel=\"nofollow\" target=\"_blank\">ir@altimmune.com<\/a><\/p>\n<p>\n        <strong>Media Contact:<br \/><\/strong>Real Chemistry\u00a0<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=FUP3sOk4zp9WGL7e7-foXGMBENNribzUHg6gqQEaS8gyMsEdsQmjlO6597ewBcg-cHmSr_SJhlrbkUxUPKqJesrj8N0OCWrtgkUa4gGAtfN1OmEJ4VXDek9I5bXlyf5jQa5xus9_4fuvUcQuk_PvY_ZkLt1FuFSIWCdeiubfAXFRAfCoEAHs-JNJ0M3f0r20nEnxr4nUL90ucYjFRDoA2OTs-H5n-ZqjAsH-aRQbnXL5ACsci2aYwFKVuMDyFHJNUx8fQGfOsfrwQDwv0kAYTrbPBLtmEXjg4mmhZzEI9l9Btqw7JvfxOKnpUkROtXR2dCnF_0zuoNvtJIZW_t_w1O_1YnthaEdjQ_N3HvUf5yxn2aBpHJTyJvh6CoKMOzDaHrt-BUPfoysGegKtkvFDl4c-qbdqcM1LsuteLjdRLBJ3XoZtdaTXnoQp4yVNzVfEPoC7-ZlKaX_0CheueWCKQQYpDTWsld7tf8Bm3oCXk9Yr2N-yl722dgEDVAu5iMqSZV-20AMv_y7nJ4XpQWAzeEihwyOxWdRkcIl0GhSlZDlut1I7KX6u9zigiveTaeem\" rel=\"nofollow\" target=\"_blank\">altimmune@realchemistry.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc5OTAzMSM3NzQ1OTEyIzIwMTA2NzY=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZjI1ZWM2ZjQtYWZmOC00NTI4LWExZDktYzRjYzk0ZmFiNzdjLTEwMjIyNDktMjAyNi0wNy0yOC1lbg==\/tiny\/Altimmune-Inc.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Pemvidutide 2.4 mg delivered a statistically significant and clinically meaningful reduction in heavy drinking days, the primary endpoint of the trial\u00a0 Important secondary endpoints were also met, including two-level reduction in WHO risk drinking levels and zero heavy drinking days, both of which are recognized by the FDA as registrational endpoints A generally favorable tolerability profile was observed in the trial Conference call to be held today at 8:00 am ET GAITHERSBURG, Md., July 28, 2026 (GLOBE NEWSWIRE) &#8212; Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company focused on serious liver diseases, today announced positive topline results from the RECLAIM Phase 2 trial evaluating pemvidutide, an investigational balanced glucagon\/GLP-1 dual receptor agonist, in patients with moderate to severe alcohol &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-announces-positive-topline-results-from-reclaim-phase-2-trial-of-pemvidutide-in-alcohol-use-disorder\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Altimmune Announces Positive Topline Results from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-985423","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Altimmune Announces Positive Topline Results from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-announces-positive-topline-results-from-reclaim-phase-2-trial-of-pemvidutide-in-alcohol-use-disorder\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Altimmune Announces Positive Topline Results from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Pemvidutide 2.4 mg delivered a statistically significant and clinically meaningful reduction in heavy drinking days, the primary endpoint of the trial\u00a0 Important secondary endpoints were also met, including two-level reduction in WHO risk drinking levels and zero heavy drinking days, both of which are recognized by the FDA as registrational endpoints A generally favorable tolerability profile was observed in the trial Conference call to be held today at 8:00 am ET GAITHERSBURG, Md., July 28, 2026 (GLOBE NEWSWIRE) &#8212; Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company focused on serious liver diseases, today announced positive topline results from the RECLAIM Phase 2 trial evaluating pemvidutide, an investigational balanced glucagon\/GLP-1 dual receptor agonist, in patients with moderate to severe alcohol &hellip; Continue reading &quot;Altimmune Announces Positive Topline Results from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-announces-positive-topline-results-from-reclaim-phase-2-trial-of-pemvidutide-in-alcohol-use-disorder\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-28T11:04:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc5OTAzMSM3NzQ1OTEyIzIwMTA2NzY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"10 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-announces-positive-topline-results-from-reclaim-phase-2-trial-of-pemvidutide-in-alcohol-use-disorder\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-announces-positive-topline-results-from-reclaim-phase-2-trial-of-pemvidutide-in-alcohol-use-disorder\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Altimmune Announces Positive Topline Results from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder\",\"datePublished\":\"2026-07-28T11:04:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-announces-positive-topline-results-from-reclaim-phase-2-trial-of-pemvidutide-in-alcohol-use-disorder\\\/\"},\"wordCount\":1975,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-announces-positive-topline-results-from-reclaim-phase-2-trial-of-pemvidutide-in-alcohol-use-disorder\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc5OTAzMSM3NzQ1OTEyIzIwMTA2NzY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-announces-positive-topline-results-from-reclaim-phase-2-trial-of-pemvidutide-in-alcohol-use-disorder\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-announces-positive-topline-results-from-reclaim-phase-2-trial-of-pemvidutide-in-alcohol-use-disorder\\\/\",\"name\":\"Altimmune Announces Positive Topline Results from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-announces-positive-topline-results-from-reclaim-phase-2-trial-of-pemvidutide-in-alcohol-use-disorder\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-announces-positive-topline-results-from-reclaim-phase-2-trial-of-pemvidutide-in-alcohol-use-disorder\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc5OTAzMSM3NzQ1OTEyIzIwMTA2NzY=\",\"datePublished\":\"2026-07-28T11:04:35+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-announces-positive-topline-results-from-reclaim-phase-2-trial-of-pemvidutide-in-alcohol-use-disorder\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-announces-positive-topline-results-from-reclaim-phase-2-trial-of-pemvidutide-in-alcohol-use-disorder\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-announces-positive-topline-results-from-reclaim-phase-2-trial-of-pemvidutide-in-alcohol-use-disorder\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc5OTAzMSM3NzQ1OTEyIzIwMTA2NzY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc5OTAzMSM3NzQ1OTEyIzIwMTA2NzY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/altimmune-announces-positive-topline-results-from-reclaim-phase-2-trial-of-pemvidutide-in-alcohol-use-disorder\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Altimmune Announces Positive Topline Results from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Altimmune Announces Positive Topline Results from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-announces-positive-topline-results-from-reclaim-phase-2-trial-of-pemvidutide-in-alcohol-use-disorder\/","og_locale":"en_US","og_type":"article","og_title":"Altimmune Announces Positive Topline Results from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder - Market Newsdesk","og_description":"Pemvidutide 2.4 mg delivered a statistically significant and clinically meaningful reduction in heavy drinking days, the primary endpoint of the trial\u00a0 Important secondary endpoints were also met, including two-level reduction in WHO risk drinking levels and zero heavy drinking days, both of which are recognized by the FDA as registrational endpoints A generally favorable tolerability profile was observed in the trial Conference call to be held today at 8:00 am ET GAITHERSBURG, Md., July 28, 2026 (GLOBE NEWSWIRE) &#8212; Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company focused on serious liver diseases, today announced positive topline results from the RECLAIM Phase 2 trial evaluating pemvidutide, an investigational balanced glucagon\/GLP-1 dual receptor agonist, in patients with moderate to severe alcohol &hellip; Continue reading \"Altimmune Announces Positive Topline Results from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-announces-positive-topline-results-from-reclaim-phase-2-trial-of-pemvidutide-in-alcohol-use-disorder\/","og_site_name":"Market Newsdesk","article_published_time":"2026-07-28T11:04:35+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc5OTAzMSM3NzQ1OTEyIzIwMTA2NzY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"10 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-announces-positive-topline-results-from-reclaim-phase-2-trial-of-pemvidutide-in-alcohol-use-disorder\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-announces-positive-topline-results-from-reclaim-phase-2-trial-of-pemvidutide-in-alcohol-use-disorder\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Altimmune Announces Positive Topline Results from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder","datePublished":"2026-07-28T11:04:35+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-announces-positive-topline-results-from-reclaim-phase-2-trial-of-pemvidutide-in-alcohol-use-disorder\/"},"wordCount":1975,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-announces-positive-topline-results-from-reclaim-phase-2-trial-of-pemvidutide-in-alcohol-use-disorder\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc5OTAzMSM3NzQ1OTEyIzIwMTA2NzY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-announces-positive-topline-results-from-reclaim-phase-2-trial-of-pemvidutide-in-alcohol-use-disorder\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-announces-positive-topline-results-from-reclaim-phase-2-trial-of-pemvidutide-in-alcohol-use-disorder\/","name":"Altimmune Announces Positive Topline Results from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-announces-positive-topline-results-from-reclaim-phase-2-trial-of-pemvidutide-in-alcohol-use-disorder\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-announces-positive-topline-results-from-reclaim-phase-2-trial-of-pemvidutide-in-alcohol-use-disorder\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc5OTAzMSM3NzQ1OTEyIzIwMTA2NzY=","datePublished":"2026-07-28T11:04:35+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-announces-positive-topline-results-from-reclaim-phase-2-trial-of-pemvidutide-in-alcohol-use-disorder\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-announces-positive-topline-results-from-reclaim-phase-2-trial-of-pemvidutide-in-alcohol-use-disorder\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-announces-positive-topline-results-from-reclaim-phase-2-trial-of-pemvidutide-in-alcohol-use-disorder\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc5OTAzMSM3NzQ1OTEyIzIwMTA2NzY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc5OTAzMSM3NzQ1OTEyIzIwMTA2NzY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/altimmune-announces-positive-topline-results-from-reclaim-phase-2-trial-of-pemvidutide-in-alcohol-use-disorder\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Altimmune Announces Positive Topline Results from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/985423","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=985423"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/985423\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=985423"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=985423"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=985423"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}